Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy
NCT02860923 on ClinicalTrials.gov · last registry update 2026-05-22
A small phase 3 — 42 participants, against a typical 424. The sponsor logged completion for 30 June 2018. Primary outcome, as filed: Compare body weight change thanks to weighing machine. exenatide is approved in the US, but not for obesity — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P3
- Drug
- exenatideBydureon, Byetta
- Sponsor
- University Hospital, Bordeaux
- Sponsor type
- Other
- Enrollment
- 42
- Started
- 2017-01-11
- Primary completion
- 2018-06-30 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Compare body weight change thanks to weighing machine
Conditions studied
Craniopharyngiomas · Hypothalamic Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.